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short palindromic repeat; sgRNA, single guide RNA; FUT8, α-1,6-Fucosyltransferase 8; 
B4GALT, β-1,4-Galactosyltransferase; DSB, double stand break; NHEJ, non-homologous 
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Acidaminococcus_sp_BV3L6 Cpf1; LbCpf1, Lachnospiraceae_bacterium_ND2006 Cpf1; GUSB, 
β-Glucuronidase; gDNA, genomic DNA; F-LCA, Fluorescein labeled Lens Culinaris 
Agglutinin; NucRed, NucRed® Live 647 ReadyProbes®; FACS, fluorescence activated cell 
sorting; cDNA, copy DNA; RT-qPCR, Reverse Transcription qPCR; DIG, Digoxigenin-
labeled; GAPDH, Glyceraldeyde-3-phoshate Dehydrogenase; PAM, protospacer adjacent 
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Abstract 
Since the establishment of clustered regularly interspaced short palindromic repeat 
(CRISPR)/Cas9, powerful strategies for engineering of CHO cell lines have emerged. 
Nevertheless, there is still room to expand the scope of the CRISPR tool box for further 
applications to improve CHO cell factories. 
Here, we demonstrate activity of the alternative CRISPR endonuclease Cpf1 in CHO-K1 for 
the first time and that it can be used in parallel to CRISPR/Cas9 without any interference. 
Both, Cas9 and Cpf1, can be effectively used for multi-gene engineering with a strategy 
based on paired single guide RNAs (sgRNAs) for full gene deletions. This strategy also 
enables the targeting of regulatory regions, which would not respond to the conventional 
frameshift mutations, as shown by deleting the α-1,6-Fucosyltransferase 8 (FUT8) 
promoter resulting in a functional knock-out. Fut8 also served as model to verify that 
deletion efficiency is size-independent (2 – 150 kb). 
To test the efficiency of multi-gene approaches in combination with gene deletion, clones 
harboring triple deletions in β-1,4-Galactosyltransferase (B4GALT) isozymes were 
identified using solely conventional PCR/qPCR. In addition two bicistronic transcription 
strategies were implemented to enable unequivocal pairing of sgRNAs: a CHO-derived tRNA 
linker that works for both, Cas9 and Cpf1, as well as paired sgRNAs in an array format, which 
can be used with Cpf1 due to its RNA processing ability. 
These strategies broaden the range of application of CRISPR for novel gene editing 
approaches in CHO cells and also enable the efficient realization of a genome-wide deletion 
library. 
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1 Introduction 
Chinese Hamster Ovary (CHO) cells are the most widely used expression system for the 
production of complex therapeutic proteins since their establishment as cell factories in 
1987 [1]. Despite the importance of CHO cells for industry, it was only recently that genomic 
and transcriptomic data of high quality was acquired [2–4]. However, now, that such data 
sets are available, the focus of optimization of cell performance has shifted from the original 
approach of optimizing media, cell selection procedures and production process conditions, 
towards directed cell engineering [5]. 
In parallel, the development of tools for targeted cell engineering has made a tremendous 
leap forward with the introduction of nucleases derived from bacterial clustered regularly 
interspaced short palindromic repeat (CRISPR) immune systems. Cas9, originally identified 
as the effector endonuclease of Streptococcus pyogenes [6], has been proven to be an 
efficient editing tool in many mammalian cells using a single chimeric RNA guide (single 
guide RNA - sgRNA) [7]. Cas9 introduces DNA double strand breaks (DSB), which are 
repaired by either homology directed repair or non-homologous end-joining (NHEJ), with 
the latter being the more frequent mechanism in mammalian cells [8]. NHEJ usually results 
in the insertion or deletion (InDel) of nucleotides at the targeted site. With CRISPR/Cas9, 
genes can be disrupted in a low-cost and time-saving manner, while ensuring high 
specificity for a large panel of targets [7]. Therefore, it is now possible to bring cell 
engineering to the next level: by combining numerous deletions of protein-coding regions 
and non-coding regulatory elements, entire cellular pathways can be either altered or 
completely blocked. 
Cas9 has already been used quite extensively in CHO cells [9,10] and further development 
of CRISPR based tools is happening at a rapid pace. Cpf1, a CRISPR class 2 type V enzyme, 
was recently introduced as an alternative editing system [11]. Two Cpf1 variants derived 
from Acidaminococcus_sp_BV3L6 (AsCpf1) and Lachnospiraceae_bacterium_ND2006 
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(LbCpf1) were already found to be active in human cell lines [12]. Published work based on 
this novel system is limited and to our knowledge, its efficient use in CHO cells has not yet 
been demonstrated. Similar to Cas9, Cpf1 is an endonuclease guided by short RNA 
sequences and has an additional RNase activity [13]. Furthermore, Cpf1 has divergent 
properties in terms of recognition sequence, exact site of cutting and length of sgRNA. Due 
to these differences Cpf1 further broadens the range of possible applications for targeted 
engineering [14]. Specific characteristics of Cpf1 in comparison to the features of Cas9 are 
summarized in Tab. 1. 
In most previous publications CRISPR/Cas9-mediated gene disruptions were introduced 
within the coding region of the targeted protein via a single sgRNA [15,16]. Hence, gene 
disruption is mostly based on frameshift mutations, which will statistically occur in only 
two out of three cases [17]. Usually sites for targeting are chosen that ensure loss-of-
function (LOF): they are either located close to the translational start site or within a 
sequence that encodes for a crucial domain of the protein [16]. However, this approach 
raises several potentially problematic issues including altered transcripts or splicing 
variants, which could compensate or change gene function, as well as the accumulation of 
incomplete protein or of (frame-shifted) nonsense protein sequences [17]. Thus, we believe 
that to study a protein’s role in a chosen system, it is necessary to remove the protein, which 
can only be ensured if the entire gene and thus its expression is completely eliminated as 
has been done by Hu et al. to investigate C-terminal lysine cleavage in antibody-producing 
CHO cells [18]. 
To achieve such complete removal of genes of interest, a combination of two sgRNAs needs 
to be transfected, leading to the loss of the intervening DNA sequence [19–22]. Although, 
the correlation between deletion frequency and deletion size was examined in human cells 
extensively reaching over one megabase, the link between genomic deletion range and the 
corresponding efficiency has not yet been evaluated in CHO [17,21]. To efficiently use such 
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an approach, especially in the context of multiple gene knockouts in the same cell, the 
establishment of strategies for bicistronic transcription of sgRNA pairs is of advantage. Such 
strategies have been introduced with expression vectors using various linkers including 
tRNAs, RNA-triple-helix, introns, microRNAs and ribozyme sequences [23–25]. Bicistronic 
transcription with tRNAs has several benefits over other systems: the sequence is rather 
short and most importantly, post-transcriptional processing is efficiently conducted by the 
cell´s endogenous machinery. The RNase activity of Cpf1 may turn out to be specifically 
beneficial in this context, as the autologous cleavage of sgRNAs allows further reduction of 
the overall length of bicistronic constructs as no linker regions are required [26]. Thus, such 
a strategy could be used for the generation of a genome-wide knock-out library, where the 
corresponding sgRNA pairs need to be tightly linked: the shorter the sequence to be 
synthesized for the library, the simpler it is to design and the more cost-efficient. 
The following study aims to evaluate additional tools for CHO cell genome editing, with a 
view of enabling just such a genome-wide deletion library. Towards this end, the efficiency 
of such deletions was tested to be size-independent and the possibility to target also non-
coding regions of the genome was evaluated by excising the promoter region of FUT8. 
Furthermore, different bicistronic sgRNA transcription strategies for Cas9 and AsCpf1 were 
established. 
This paired sgRNA strategy allows screening for deletions by conventional PCR and 
abolishes the need for sequencing or other time-consuming methods for initial cell 
selection, thus enabling rapid and efficient selection of cell lines harboring multiple 
deletions. 
 
2 Materials and methods 
All gRNAs, gBlocks, primers for PCR/qPCR reactions and vector construction as well as 
probes used in Northern Blot analysis are listed in supporting information. 
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2.1 Cloning of gRNAs into CRISPR/Cas9 vector 
The vector pX458 (pSpCas9(BB)-2A-GFP, #48138, Addgene) was used for introducing 
modifications in CHO-K1 cells mediated by Cas9 [7]. This plasmid allows expression of Cas9 
and additionally encodes for a second cassette with a cloning backbone for sgRNA 
expression from a U6 promoter. gRNAs with a length of 20 nt were designed with the help 
of the CRISPR guide online tool provided by Benchling and selected based on the probability 
of off-targets [27] and their predicted on-site activity [28]. The selected guide sequences 
were cloned into the pX458 vector as described by Bauer et al. [22]. 
 
2.2 Construction of vectors for CRISPR/Cpf1 and cloning of gRNAs 
All-in-one plasmids were generated for AsCpf1 and LbCpf1. pY010 (pcDNA3.1-hAsCpf1, 
#69982, Addgene) and pY016 (pcDNA3.1-hLbCpf1, #69988, Addgene) served as 
backbones. The U6 promoter with two downstream BsmBI and flanking PciI sites was 
amplified from pX458 using Phusion High-Fidelity DNA Polymerase (Thermo Fisher 
Scientific) with a three-step PCR followed by a two-step PCR. The amplified U6-BsmBI unit 
was inserted via PciI into pY010 and pY016. Additionally, Gibson Assembly reaction was 
performed to clone T2A-GFP derived from pX458 into the BamHI restriction site of modified 
pY010 and pY016. The NEBuilder® HiFi Assembly Cloning Kit, containing a Q5® High-
Fidelity DNA Polymerase, was used for this purpose. Newly generated all-in-one plasmids 
are referred to as pY010(AsCpf1) and pY016(LbCpf1). 
AsCpf1 and LbCpf1 gRNA sequences of 23 nt were designed as described in section 2.1. 
Chosen gRNAs with the scaffold sequence (21 nt) at the 5´-end and a 3’-Poly(T) tail were 
cloned according to Bauer et al. into the Cpf1 plasmids using BsmBI. 
 
2.3 Cell culture and transfection 
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CHO-K1 cells were routinely cultivated in CD-CHO medium (Thermo Fisher Scientific) 
supplemented with 8 mM Glutamine (Sigma-Aldrich) and 0.2% Anti-Clumping Agent 
(Thermo Fisher Scientific). Cells were grown in either 125 ml shaking flasks (Corning) with 
a working volume of 25 – 30 ml or in 50 ml spin bioreactor tubes (Techno Plastic Products) 
in 5 – 10 ml medium. Shaking flasks and spin tubes were incubated at 37°C, 7% CO2 and 
humidified air at a shaking speed of 140 rpm and 250 rpm, respectively. 
Nucleofection was done with a Neon® Nucleofector and the 100 µl Neon® Transfection Kit 
(Thermo Fisher Scientific) with 1700 V and 1 pulse of 20 ms. Typically, 5 x 106 cells in 
exponential growth phase were spun down and resuspended in 100 µl resuspension buffer 
containing 10 – 30 µg endotoxin-free plasmid DNA. CHO-K1 cells transfected with TE buffer 
(mock) or the appropriate amount of the empty CRISPR all-in-one vector lacking a specific 
gRNA sequence (scramble) were used as controls/references for downstream analysis. 
Transfection efficiencies were determined one or two days’ post transfection by flow 
cytometry (Gallios, Beckman Coulter) measuring the percentage of GFP-expressing cells. 1 
x 104 cells were analyzed using a 488 nm argon laser with a 525/50 filter. A minimum of 
70% GFP positive cells was expected. 
 
2.4 Determination of sgRNA activity 
The activity of individual sgRNAs was tested by detecting introduced InDel mutations using 
the Surveyor® Mutation Detection Kit (Integrated DNA Technologies). Genomic DNA 
(gDNA) was isolated on day four post transfection with the DNeasy® Blood & Tissue Kit 
(Qiagen) according to the manufacturer´s protocol. For the first step of the Surveyor® assay 
the targeted genomic sites were amplified using Phusion High-Fidelity DNA Polymerase 
(Thermo Fisher Scientific). The mismatch detecting Surveyor® Nuclease assay was 
performed according to the manufacturer´s protocol. The degree of InDel formation was 
determined via evaluation of DNA fragmentation by agarose gel electrophoresis using 
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Midori Green Advance (Biozym) for DNA staining and ImageQuantTM for visual analysis. 
Relative InDel rates were calculated as described by Zetsche et al., 2015 [12]. 
 
2.5 Crosstalk between CRISPR/Cas9 and CRISPR/Cpf1 
The U6-sgRNA sequences targeting FUT8 exon 2 for Cas9, AsCpf1 and LbCpf1 were PCR 
amplified with Phusion High-Fidelity DNA Polymerase (Thermo Fisher Scientific). PCR 
reactions were purified using the DNA Clean & ConcentratorTM-5 from Zymo Research as 
recommended. Here, 1 x 106 CHO-K1 cells were transfected either with 5 µg of the all-in-
one plasmids as positive controls or co-transfected with CRISPR enzyme plasmids with 
different combinations of the U6-sgRNA PCR products with a minimal requirement of 35% 
GFP positive cells. Crosstalk between Cas9 and AsCpf1/LbCpf1 was investigated by 
Surveyor assay analysis. 
 
2.6 Detection of genomic deletion of FUT8 
The generated FUT8 deletions were analyzed on genomic level by non-deletion and deletion 
PCR [22] as well as qPCR. gDNA was isolated four days after co-transfection of CHO-K1 cells 
with the appropriate Cas9 sgRNA combinations (10 µg each). Non-deletion PCR was 
routinely performed with GoTaq® G2 DNA Polymerase (Promega). For deletion PCRs, 
Phusion High-Fidelity DNA Polymerase (Thermo Fisher Scientific) was used with a 
maximum elongation time of 30 sec. Non-deletion as well as deletion PCR products were 
visualized on a 2% TAE agarose gel stained with Midori Green Advance (Biozym). 
Genomic deletion efficiencies were quantified by qPCR. Samples were measured in 
quadruplicates using the SensiFASTTM SYBR® Hi-ROX Kit (Bioline) with 20 ng gDNA as 
template and a reaction volume of 20 µL. qPCRs were run on a Rotor-Gene qPCR cycler 
(Qiagen) with 40 cycles of amplification. Average fold changes in FUT8 gDNA level 
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normalized to β-Glucuronidase (GUSB) and relative to the mock were determined with the 
2-∆∆CT method [29]. 
To analyze the phenotypic change of FUT8 deletion cell pools, Fluorescein-labeled Lens 
Culinaris Agglutinin (F-LCA, Vector Laboratories) staining in combination with flow 
cytometry (Gallios, Beckman Coulter) was performed one week after transfection. 
Additionally, cells were treated with NucRed® Live 647 ReadyProbes® (NucRed, Life 
Technologies) to detect live cells. 1 x 106 cells were washed once with PBS and incubated 
for 45 min at room temperature in the dark in complete medium containing 20 µg/mL F-
LCA and two drops of NucRed. Cells were washed twice with complete medium before 
resuspension in it. 1 x 104 cells were analyzed by measuring green and red fluorescence 
using a 488 nm argon laser with a 525/50BP filter and a HeNe 633 nm laser with a 660BP 
filter. 
 
2.7. Generation of cell lines with multiple deletions in N-Glycosylation genes 
For the generation of triple CHO-K1 knock-out cell lines, three subsequent rounds of 
transfection were performed, in which single genes were targeted by co-transfection of two 
pX458-sgRNA vectors using 15 µg each. GFP positive cells were isolated by fluorescence 
activated cell sorting (FACS) on day 2 post transfection (MoFlo Astrios, Beckmann Coulter). 
Sorted cell pools were grown in cultivation medium supplemented with Penicillin-
Streptomycin (10.000 U/ml Penicillin, 10 mg/ml Streptomycin, VWR Chemicals) for three 
days. After expansion, cells were transfected with pX458 constructs targeting the next gene 
to be deleted. 
Single clones were obtained by limiting dilution cloning using 50% conditioned medium. 
Cells were seeded in 200 µl medium in 96 well plates at a cell density of two cells per well. 
Individual colonies were expanded in 900 µl in 48 well plates and incubated at 37°C, 7% 
CO2 and humidified air at a shaking speed of 300 rpm. Samples for colony PCR were 
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prepared by cell lysis in 20 µl 0.2 M NaOH (10 min at 75°C, neutralization with 180 µl 0.04 
M TRIS-HCl, pH 7.8) and subjected to three individual non-deletion PCR reactions for each 
gene. Lysates of selected clones were further evaluated by deletion PCR for all three genes. 
Total RNA of 1 - 5 x 106 cells was isolated using TRI® reagent (Sigma-Aldrich, USA). Copy 
DNA (cDNA) for Reverse Transcription qPCR (RT-qPCR) was generated from 800 ng RNA 
using the High-Capacity cDNA Reverse Transcription Kit with RNase Inhibitor (Thermo 
Fisher Scientific) in reactions of 20 µl according to the instructions provided. 
cDNA was diluted 1:5 with nuclease-free water and RT-qPCRs were run in accordance to 
the protocol for gDNA qPCR. Here, 1 µl diluted cDNA was used as template in 10 µL reaction 
volume and Glyceraldeyde-3-phoshate Dehydrogenase (GAPDH) transcript levels served as 
internal control for normalization. 
 
2.8 Bicistronic sgRNA transcription 
Bicistronic sgRNAs containing the tRNA linker were ordered as gBlocks from Integrated 
DNA Technologies (IDT) with flanking cloning sites for both CRISPR systems. Arrayed 
AsCpf1 sgRNAs were ordered as single-stranded oligonucleotides with BsmBI overhangs 
from Sigma-Aldrich, which were then annealed and phosphorylated. The double-stranded 
AsCpf1 array as well as the tRNA gBlocks targeting FUT8 were inserted into the CRISPR all-
in-one plasmids (pX458 and pY010(AsCpf1)) with BsmBI and BbsI. Intracellular processing 
of bicistronically transcribed sgRNAs was investigated by non-radioactive Northern Blot. 
Total RNA from transfected cells was isolated two days post treatment. For each sample 
20 μg RNA were resolved by a 10% TBE-Urea-PAGE gel (Invitrogen) and blotted onto a 
Hybond-N+ nylon membrane (Roche). The membrane was cross-linked by ultraviolet light 
and hybridized overnight with Digoxigenin-labeled (DIG) probes (DIG Oligonucleotide 
Tailing Kit, 2nd generation, Roche). DIG Luminescent Detection Kit (Roche) was used for 
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detection according to manufacturer’s manual. Functionality of released Cas9 or AsCpf1 
sgRNAs against FUT8 was determined by F-LCA staining eleven days post transfection. 
 
3 Results 
 
3.1 Activity of CRISPR/Cpf1 in CHO-K1 and crosstalk with CRISPR/Cas9 
Initially, the two Cpf1 enzymes, AsCpf1 and LbCp1, were examined for their functionality in 
CHO.  AsCpf1 and LbCpf1 all-in-one plasmids were generated containing a T2A-linked GFP 
transfection marker and a U6 promoter for expression of sgRNAs together with two BsmBI 
restriction sites (Fig. 1A). Next, overlapping gRNAs for Cas9 as well as for AsCpf1 and 
LbCpf1 targeting FUT8 exon 2 (Fig. 1B) were designed to verify Cpf1 activity and the 
functionality of the modified vectors. Relative InDel modification rates of 21%, 19% and 
12% were estimated for AsCpf1, LbCpf1 and Cas9 respectively (Fig. 1C). To enable multiple 
parallel deletion approaches that can be controlled independently of each other, potential 
crosstalk between the two Cpf1 enzymes and the Cas9 system was evaluated. Therefore, 
CRISPR enzyme expressing vectors were transfected together with U6-sgRNA PCR products 
for the different CRISPR systems in every possible combination (Fig. 1D). The all-in-one 
plasmids, already used for the analysis of AsCpf1 and LbCpf1 activity in CHO-K1, served as 
positive controls. The mock sample and each scramble control were used as negative 
controls (Fig. 1E). The respective positive controls as well as the suitable combinations of 
Cas9, AsCpf1 and LbCpf1 enzyme plasmid together with the corresponding U6-sgRNA PCR 
product resulted in detectable genome modifications (Cas9: 18% and 9%, AsCpf1: 27% and 
11%, LbCpf1: 17% and 10%). There were no indications for the presence of DNA cleavage 
when using one of the CRISPR enzyme expressing plasmids in combination with one of the 
other CRISPR system’s U6-sgRNA PCR products. AsCpf1 was selected for further 
development of the CRISPR tool box in CHO. 
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3.2 Evaluation of genomic deletion size and modification efficiency using co-
transfected sgRNA pairs 
FUT8 was selected as a model gene to establish the strategy for generating LOF mutations 
by full genomic deletion of targeted gene using two CRISPR/Cas9 sgRNAs. At the same time 
the feasible genomic deletion range and the corresponding efficiency was evaluated. FUT8 
is the only enzyme responsible for core α-1,6-fucosylation in CHO-K1 cells both for secreted 
and surface proteins [2]. Therefore, it offers the possibility to easily determine the efficiency 
of deletions by monitoring the binding of a specific lectin to the cell surface. Six different 
CRISPR/Cas9 gRNAs were generated targeting untranslated parts of the gene and their 
functionality was evaluated via Surveyor assay analysis (Supporting information, Fig. S1). 
Depending on the combination of sgRNAs for co-transfection, genomic deletions ranging 
from approximately 2 kb up to 150 kb were covered. Additionally, a pair of sgRNAs was 
cloned to target the FUT8 promoter (Fig. 2A) as identified based on the CHO Epigenome 
database [30]. The workflow for the analysis of genomic deletions and their efficiencies is 
depicted in Figure 2B. The occurrence of genomic deletions was verified by amplifying the 
targeted regions for non-deletion and deletion PCR. A decrease in non-deletion PCR signal 
intensities was observed for all FUT8 deletion cell pools except when targeting the 
promoter, since the diagnostic primer pair is binding within the FUT8 gene. Relative 
intensities were determined ranging from 65 – 85 % compared to the mock control. 
Furthermore, deletion PCR bands were obtained for all FUT8 modified samples (Fig. 2C). To 
quantify the reduction of intact gene copies in the pools, we determined the FUT8 gDNA fold 
change by qPCR (Fig. 2D). Here, the used primer pair was binding within the FUT8 gene and 
is therefore not applicable to determine the deletion efficiency for the FUT8 promoter 
sample. An average reduction of 0.30 ± 0.05 fold relative to the mock control was detected 
for all other deletion pools. The level of reduction was independent of the deletion size. 
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Further, FUT8 LOF mutations were analyzed in the modified CHO-K1 cell pools using F-LCA 
staining (Fig. 2E; supporting information, Fig. S3). For the gene deletion samples between 
40 – 60% of analyzed cells were F-LCA negative, indicating a significant reduction of FUT8 
expression one week after transfection. Moreover, targeting the FUT8 promoter also 
resulted in a decrease of F-LCA positive cells of around 20%. A comparable change in 
phenotype was not observed when using each sgRNA individually except for sg7, which is 
binding close to the approximate exon (Supporting information, Fig. S2 and Fig. S6). 
 
3.3 Generation of clones with multiple deletions in N-Glycosylation genes 
In the context of pathway engineering, it may be necessary to remove several genes to 
completely inactivate or modify a pathway. Likewise, in the context of isoenzymes it is often 
unclear what the precise functions and contributions of the individual enzymes are. This 
would require deleting several isoenzymes in parallel to leave a single isoform for in depth 
characterization. To evaluate our full deletion strategy for multiplexing, we chose three 
isoforms of B4GALT and targeted them by paired sgRNAs as depicted in Figure 3A. The 
fragments to be excised from the genome have a size of 18.3, 5.2 and 18.9 kb for B4GALT1, 
B4GALT2 and B4GALT4, respectively. Figure 3B shows the outline of the workflow. A 
deletion for each gene was introduced consecutively in three subsequent rounds of 
transfection and sorting for GFP expression. 144 clones obtained by single cell dilution were 
expanded and in the first round of screening, non-deletion PCR was performed for all three 
targets (Supplementary information, Fig. S3). At this stage many clones were already 
excluded as they still had at least one gene copy of the individual targets, resulting in a 
subset of 23 clones, which showed non-deletion and deletion PCR profiles suggesting full 
deletion of two (n = 21) or three genes (n = 2). Out of these 23 clones, 17 were selected for 
further investigation to obtain similar clone numbers for each combination. For clone 
characterization, RNA was isolated and RT-qPCR was performed to verify lack of expression 
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of targeted galactosyltransferases to ensure LOF. Analysis by RT-qPCR resulted in 
identification of a total of three clones with no detectable expression of all three targets 
(Supplementary information, Fig. S4). One potential triple knock-out clone was proven to 
have been incorrectly suspected to carry three deletions, while two potential double knock-
out clones also lacked expression of the residual third target. Here analysis by non-deletion 
and deletion PCR suggest that both clones had one copy of B4GALT2 deleted, while the other 
was edited in a way that precludes transcription. Furthermore, five clones showed to have 
two genes deleted (B4GALT1/2 deletion: four clones, B4GALT1/4 deletion: one clone) and 
seven clones with either B4GALT1 or B4GALT2 fully knocked-out were identified (Fig. 3C). 
Thus, of all possible combinations for this set of paired sgRNAs, the only two missing after 
this approach was a B4GALT2/4 double and a B4GALT4 single deletion (Supplementary 
information, Fig. S4). 
 
3.4 Bicistronic sgRNA transcription for CRISPR/Cas9 and CRISPR/AsCpf1 in CHO-K1 
To permit sgRNA delivery of a defined pair into the same cell to induce a specific genomic 
deletion, which would be a prerequisite for the realization of a full genome deletion library, 
we implemented bicistronic sgRNA transcription strategies for Cas9 and AsCpf1 (Fig. 4A). 
To remain within the endogenous CHO system, a CHO tRNAGly sequence was used to link a 
specific sgRNA pair and to force their intracellular processing by endogenous RNase 
enzymes. Design of bicistronic sgRNA cassettes resulted in a total length of around 270 nt 
(Cas9) and 165 nt (AsCpf1), respectively. Additionally, we constructed an AsCpf1 sgRNA 
array system without any extra linker for Cpf1 RNase-mediated intracellular editing, thus 
reducing the bicistronic sgRNA length further to 86 nt. To verify RNA processing and to 
prove functionality of the released guides, sgRNAs to introduce 12.5 kb (Cas9) or 50.9 kb 
(AsCpf1) genomic FUT8 deletions were tested by transfection of CHO-K1 cells with plasmids 
containing either the linked sgRNA pair or with vectors expressing the same sgRNAs 
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individually as positive control. Northern Blot analysis of total RNA using DIG- labeled 
probes against the Cas9 scaffold and the AsCpf1 sgRNA targeting FUT8 exon 2 were 
performed (Fig. 4B). In case of Cas9 a single band was observed for the two plasmid 
approach as well as for the sgRNA-tRNA system with a size of approximately 100 nt. The 
same results were obtained for both AsCpf1 bicistronic sgRNA transcription approaches, 
with bands at the expected size of around 45 nt. Next, the CRISPR enzyme guiding capability 
of intracellularly released sgRNAs for all three different paired transcription strategies was 
evaluated by F-LCA (Fig. 4C; supporting information, Fig. S6). For CRISPR/Cas9 a reduction 
of the F-LCA positive cell population by about 15% ± 7% was observed when transfecting 
CHO-K1 cells with the two plasmid approach as well as the sgRNA-tRNA carrying plasmid. 
The spiked sample, which is composed of the scrambled plasmid and the sgRNA-tRNA 
vector to achieve similar molecular amounts of sgRNAs compared to the two plasmid 
approach, resulted in a reduction of F-LCA positive cells by around 5%. Targeting FUT8 with 
AsCpf1 sgRNA pairs decreased the percentage of F-LCA positive cells by overall 14% ± 5%. 
Here, co-transfection of the separate sgRNA expressing plasmids induced a signal reduction 
of 8%, while the sgRNA-tRNA approach spiked with the scrambled plasmid induced a 10% 
reduction. Both, the sgRNA-tRNA strategy as well as the sgRNA array for AsCpf1 lowered 
the percentage of F-LCA positive cells by 20%, comparable to the Cas9 sgRNA-tRNA 
approach. Additionally, functionality of the released sgRNA pairs, both for Cas9 and AsCpf1, 
was evaluated by deletion PCR and gDNA qPCR (Supporting information, Fig. S7). 
 
4 Discussion 
The establishment of precision genome editing tools such as CRISPR has led to a surge in 
engineering approaches that, because of the simplicity and efficiency of these methods, 
enable strategies, which were previously considered impossible due to the high work load. 
Such scenarios include genome-wide knock-out studies as well as multi-gene pathway 
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engineering that targets several genes at the same time. However, to efficiently realize such 
strategies, the available tools require some optimization and fine-tuning. In this study, we 
propose several advancements that will help with the above. 
The most prominent limitation in this respect is the current practice of aiming to achieve 
frameshifts of coding genes for LOF generation. In a standard protocol, cells are transfected 
with a sgRNA that typically targets an exon of a functional domain or close to the 
transcription start site followed by subcloning and screening for frameshift mutations by 
sequencing. Here, on the other hand we propose a full gene deletion strategy using two 
sgRNAs, which offers several advantages compared to the InDel formation strategy: i) 
Complete deletion of a gene results in predictability of LOF [22]. ii) The efficiency in 
generating bi-allelic knock-outs is high [17]. This was proven in our study simply by the fact 
that we were able to detect significant changes in FUT8 expression, since Yamane-Ohnuki 
et al. reported that a bi-allelic FUT8 knock-out is required to obtain a discoverable LOF 
modification [31]. iii) Standard PCR and RT-qPCR are used to determine whether a cell line 
contains no, a mono- or a bi-allelic knock-out of a gene. Thus, only two PCR techniques are 
adequate for the identification of successful deletions, which is cost efficient, fast and does 
not limit the number of clones that can be screened in parallel [19]. iv) Frameshift mutation 
strategies are not applicable in case of non-coding RNAs or regulatory DNA stretches, 
however, the deletion strategy can be applied also to study the function of such genomic 
regions. We have shown that such regulatory genome editing is possible by deleting the 
FUT8 promoter. v) Most importantly, in the context of knocking out multiple genes or entire 
pathways, we speculate that frameshift mutants would eventually lead to cells filled with 
multiple dysfunctional, probably misfolded proteins that may cause unknown side effects 
and stress responses could occur, which in turn are likely to impair the cell in other ways 
than those caused by the LOF. This may have significant effects on the interpretation of 
functional studies. 
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To use such a paired sgRNA strategy for larger scale, multiplexed or genome-wide library 
driven engineering approaches, additional tools are necessary. First, the corresponding pair 
of sgRNAs needs to be transfected into a cell jointly, ideally derived from a single transcript, 
to ensure that the guides are not mixed up, which is of relevance especially in multiplexed 
or library approaches. Mainly for large-scale libraries the limiting factor is the size of the 
scaffold, which in case of Cas9 would lead to around 200 nt for a pair of sgRNAs, not 
including a linker sequence. Libraries of such length are not easily synthetized, as the 
efficient length of a nucleotide sequence that can be generated with precision is 
approximately 170 bp. Strategies to overcome this problem for paired CRISPR/Cas9 sgRNA 
libraries have been published but include additional cloning steps, which are more 
laborious and tend to have the disadvantage of increased mutation and recombination rates 
[32,33]. The use of the alternative CRISPR system Cpf1, which has a shorter scaffold and 
RNA editing abilities, enables the use of much shorter pairs of approximately 90 bp. So far, 
functionality of the alternative CRISPR enzyme Cpf1 from the two bacterial variants As and 
Lb was only proven in human cells and Drosophila [12,34]. We demonstrated efficient 
genome engineering by AsCpf1 and LbCpf1 in CHO-K1 for the first time. Since the 
established tools for paired Cas9 as well as AsCpf1 sgRNAs are either using the endogenous 
tRNA processing machinery [35] or the Cpf1 RNase activity [26] for intracellular processing 
of the bicistronic transcripts, no additional components have to be added to the system or 
transfected into cells and hence, offer an efficient approach for gene multiplexing or other 
applications. For each bicistronic sgRNA expression strategy correct intracellular editing 
was proven by Northern Blot analysis. No additional signals for unprocessed/incorrectly 
processed paired sgRNA transcripts were detected indicating that the majority of sgRNAs 
was properly released. 
The verification of the applicability of this system for CHO has additional advantages: it 
enlarges the possible range of protospacer adjacent motif (PAM) sites to AT-rich regions 
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(Cpf1 PAM is 5’-TTTN) [14], as use of Cas9 is partially restricted to GC-rich areas. 
Furthermore, it enables using CRISPR for two different intentions in the same cell without 
any crosstalk. For instance, in the above-mentioned library screening approach, one would 
want to be able to easily identify the region deleted in a given cell, which was selected for 
based on its advantageous properties. This would require that the sgRNA pair from the 
transfected library was integrated into a specific genomic locus, which would have the 
additional advantage of avoiding unspecified effects by gene disruption due to random 
integration. Thus, one would have to achieve targeted integration by CRISPR without at the 
same time allowing any genome editing of the transiently expressed sgRNAs from the 
library. To achieve this, Cas9 could be used for integration, while Cpf1 could be used for the 
subsequent deletions by the integrated sgRNA pairs [36]. 
The fact that the size of the deleted region appears to be not limited within a large range of 
2 – 150 kb enables the efficient generation of a genome-wide library of reasonable size. In 
contrast to the findings of Canver et al. [17], the modification rates for the genomic deletions 
performed in our study were size-independent and are hence, in all likelihood, more 
substantially determined by the genome engineering capability of the individual sgRNAs. 
Comparable observations were also published by Zheng et al.[19]. 
In summary, a competent strategy for the generation and screening of LOF mutants by 
inducing size-independent genomic deletions of targeted genes was demonstrated. 
Moreover, the CRISPR tool box was expanded for its application in CHO with alternative 
CRISPR/Cpf1 systems as well as bicistronic sgRNA delivery. 
The establishment of these tools now enables the realization of a genome-wide CHO 
deletion library to screen for process-relevant properties that comprises both coding and 
non-coding regions of the genome. So far, it has not been attempted to perform a genetic 
screen of this scope for this important cell line. Previous knock-out libraries established in 
other cellular systems were focusing on the protein coding regions that cover only 3% of all 
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genetic information [37,38]. We propose that it is now possible to aim for a coverage of the 
entire genome, which is of great relevance as enough evidence for the importance of 
functional non-coding regions has already accumulated.  
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Figure legends 
Table 1. CRISPR/Cpf1 features in comparison to CRISPR/Cas9 
 
 
 
Figure 1. Analysis of CRISPR/Cpf1 activity in CHO-K1 and evaluation of crosstalk between 
Cas9 and the two Cpf1 systems. (A) Illustration of all-in-one plasmid generation for AsCpf1 
and LbCpf1. (B) FUT8 exon 2 genomic sequence. Cas9 and Cpf1 gRNA sequences are 
indicated with blue or orange arrows, respectively. PAM sequences are highlighted with 
boxes in the corresponding color. (C) Surveyor assay analysis of AsCpf1 and LbCpf1 activity 
in CHO-K1. Cleaved DNA fragments were detected as smaller bands than the unmodified 
mock signal. (D) Representation of the strategy to investigate potential crosstalk between 
Cas9 and both Cpf1 systems. (E) Genome editing analysis by Surveyor assay to explore 
potential crosstalk between Cas9 and both Cpf1 tools. 
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Figure 2. Efficiency of full genomic deletion of FUT8 by co-transfected CRISPR/Cas9 sgRNA 
pairs. (A) Schematic representation of the endogenous CHO-K1 FUT8 gene (160 kb). The 
promoter is depicted as a thick arrow. Target sites for all eight generated Cas9 sgRNAs in 
intergenic, intronic or untranslated exon regions are shown with black arrows and genomic 
deletion ranges are indicated with dotted lines. Translational start site is illustrated with an 
orange arrow. (B) Graphical workflow for the experimental setup to characterize generated 
genomic deletions, repeated in three biological replicates for each deletion size. (C) Non-
deletion including relative decrease in signal intensities compared to mock control and 
deletion PCR results to identify the presence of genomic deletions (representative example 
of one biological replicate). (D) FUT8 gDNA level in modified CHO-K1 cell pools analyzed by 
qPCR, normalized against GUSB and related to the mock control (mean ± standard deviation 
of three biological replicates, each in four technical replicates). (E) Phenotypical 
characterization of the modified cell pools by F-LCA and NucRed staining. F-LCA negative 
cells require a bi-allelic FUT8 deletion. NucRed staining detects live cells (mean ± standard 
deviation of three biological replicates). 
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Figure 3. Generation of cell lines with multiple deletions in N-Glycosylation genes. (A) 
Schematic presentation of individual targets for deletion with indication of cut sites for 
selected sgRNA pairs. Fragments to be excised from B4GALT1, B4GALT2 and B4GALT4 are 
presented as dotted lines. (B) Overview of workflow including sequential rounds of 
transfection and sorting deleting only a single target at a time. (C) Results of pre-screening 
by non-deletion and deletion PCR are illustrated by the pie chart. Out of 23 clones showing 
profiles indicating triple or double deletions, 17 were subjected to further analysis by qPCR. 
The bar chart represents the final findings for clone characterization by qPCR. 
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Figure 4. Strategies for bicistronic transcription of Cas9 and AsCpf1 sgRNAs from a single 
promoter. (A) Illustrations of bicistronic sgRNA pairs for Cas9 and AsCpf1 using a CHO 
tRNAGly sequence as a linker (red). Positions for intracellular cleavage by endogenous 
RNases are indicated by purple arrows. For AsCpf1, a sgRNA array approach was 
additionally generated relying on the RNase activity of Cpf1 for processing at the site 
indicated by the orange arrow. (B) Northern Blot analysis of bicistronically transcribed Cas9 
and AsCpf1 sgRNAs using DIG-labeled probes against the Cas9 scaffold and one of the 
AsCpf1 sgRNAs. RNA from co-transfection with individual sgRNA plasmids was used as 
positive control. (C) Verification of the functionality of released Cas9 and AsCpf1 sgRNA 
pairs targeting FUT8 by phenotypical characterization of modified cell pools with F-LCA and 
NucRed staining (mean ± standard deviation of three biological replicates). 
